Drug Discov Today:纳米医学对眼部给药的治疗意义

2019-05-20 不详 网络

美国弗吉尼亚联邦大学医学院眼科的Meng T等人近日在Drug Discov Today杂志上发表了一篇综述文章,作者对纳米医学在眼部给药的研究进展进行了分析,并强调其治疗意义。

 

美国弗吉尼亚联邦大学医学院眼科的Meng T等人近日在Drug Discov Today杂志上发表了一篇综述文章,作者对纳米医学在眼部给药的研究进展进行了分析,并强调其治疗意义。

纳米医学在眼部治疗方面具有很好的潜力,与传统的眼科药物相比具有很多优势,可以有效地将眼部药物进行递送。因为纳米医学可以克服眼部障碍,改善药物释放特征并减少潜在的药物毒性。

目前,在多个层面上对眼睛进行药物递送治疗具有挑战,例如滴眼液会很快从眼表面清除,因此需要经常滴注,这对患者来说是困难的;当药物全身给药时,药物通过血-视网膜屏障运输较为困难;而局部给药时,由于角膜、结膜、巩膜和玻璃体的屏障作用,只有有限的药物可以渗透到眼睛后部。

纳米医学具有许多优于传统眼科药物的有效眼部药物递送的优势。因为纳米医学可以通过克服眼部屏障、改善药物释放曲线和减少潜在的药物毒性,进而提高治疗效果。在这篇综述中,作者强调了纳米医学对眼部给药的治疗意义。

原文出处:

Meng, T., et al., Therapeutic implications of nanomedicine for ocular drug delivery. Drug Discov Today, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080243, encodeId=41d6208024340, content=<a href='/topic/show?id=6ed0e736406' target=_blank style='color:#2F92EE;'>#纳米医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77364, encryptionId=6ed0e736406, topicName=纳米医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Feb 13 07:49:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862333, encodeId=8ff818623339f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Jan 02 11:49:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776090, encodeId=bbfc1e7609090, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 13 08:49:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953599, encodeId=55ea195359989, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Mon Sep 09 22:49:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013006, encodeId=b1622013006a0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 12 10:49:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587870, encodeId=f161158e87027, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed May 22 06:49:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080243, encodeId=41d6208024340, content=<a href='/topic/show?id=6ed0e736406' target=_blank style='color:#2F92EE;'>#纳米医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77364, encryptionId=6ed0e736406, topicName=纳米医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Feb 13 07:49:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862333, encodeId=8ff818623339f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Jan 02 11:49:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776090, encodeId=bbfc1e7609090, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 13 08:49:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953599, encodeId=55ea195359989, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Mon Sep 09 22:49:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013006, encodeId=b1622013006a0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 12 10:49:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587870, encodeId=f161158e87027, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed May 22 06:49:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2020-01-02 wangbingxhy
  3. [GetPortalCommentsPageByObjectIdResponse(id=2080243, encodeId=41d6208024340, content=<a href='/topic/show?id=6ed0e736406' target=_blank style='color:#2F92EE;'>#纳米医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77364, encryptionId=6ed0e736406, topicName=纳米医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Feb 13 07:49:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862333, encodeId=8ff818623339f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Jan 02 11:49:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776090, encodeId=bbfc1e7609090, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 13 08:49:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953599, encodeId=55ea195359989, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Mon Sep 09 22:49:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013006, encodeId=b1622013006a0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 12 10:49:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587870, encodeId=f161158e87027, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed May 22 06:49:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-12-13 huiwelcome
  4. [GetPortalCommentsPageByObjectIdResponse(id=2080243, encodeId=41d6208024340, content=<a href='/topic/show?id=6ed0e736406' target=_blank style='color:#2F92EE;'>#纳米医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77364, encryptionId=6ed0e736406, topicName=纳米医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Feb 13 07:49:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862333, encodeId=8ff818623339f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Jan 02 11:49:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776090, encodeId=bbfc1e7609090, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 13 08:49:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953599, encodeId=55ea195359989, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Mon Sep 09 22:49:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013006, encodeId=b1622013006a0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 12 10:49:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587870, encodeId=f161158e87027, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed May 22 06:49:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2080243, encodeId=41d6208024340, content=<a href='/topic/show?id=6ed0e736406' target=_blank style='color:#2F92EE;'>#纳米医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77364, encryptionId=6ed0e736406, topicName=纳米医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Feb 13 07:49:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862333, encodeId=8ff818623339f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Jan 02 11:49:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776090, encodeId=bbfc1e7609090, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 13 08:49:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953599, encodeId=55ea195359989, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Mon Sep 09 22:49:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013006, encodeId=b1622013006a0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 12 10:49:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587870, encodeId=f161158e87027, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed May 22 06:49:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2080243, encodeId=41d6208024340, content=<a href='/topic/show?id=6ed0e736406' target=_blank style='color:#2F92EE;'>#纳米医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77364, encryptionId=6ed0e736406, topicName=纳米医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Feb 13 07:49:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862333, encodeId=8ff818623339f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Jan 02 11:49:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776090, encodeId=bbfc1e7609090, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 13 08:49:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953599, encodeId=55ea195359989, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Mon Sep 09 22:49:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013006, encodeId=b1622013006a0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 12 10:49:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587870, encodeId=f161158e87027, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed May 22 06:49:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-05-22 yankaienglish

相关资讯

CANCER RES:纤维蛋白溶解酶可以增强肿瘤纳米治疗疗效

肿瘤内部高的组织间隙液体压力以及肿瘤实质导致纳米材料在肿瘤内部分布受阻,进而降低其治疗效果。肿瘤胞外基质中的纤维蛋白可能是阻止纳米材料在瘤内分布受限的原因之一。使用纤维蛋白溶解酶会降低纤维蛋白对纳米材料的阻滞作用。

Nat Commun:瑞士科学家开发可遥控纳米机器人 或可用于多种疾病治疗

2016年7月23日讯 /生物谷BIOON/ --过去几年中,全世界的科学家们都在研究如何使用微缩机器人更好地进行多种疾病治疗。这种机器人应当能够进入人体,将药物投递到特定位置或者进行精准操作,比如清除动脉血栓。科学家们希望借助这种机器人替代具有侵入性的复杂手术,使得疾病治疗能够更加优化。 来自瑞士洛桑联邦理工学院的科学家们找到了一种开发仿生机器人的简单方法,并且为这种机器人装备了许多先

STM:癌症纳米医学—从药物传递到影像

到2030年,癌症预计将会引起全世界超过1300万人死亡,是美国的第二大死亡原因。多年来,研究人员一直都在开发有前景的新方法,以提高癌症治疗和影像学的安全性和有效性。其中包括纳米技术的使用,这种技术能够靶定肿瘤,而避开健康的组织。此外,纳米技术显著提高了磁共振成像(MRI)的灵敏度,所以即使很难被发现的癌症,也能够通过纳米技术更容易地检测到它们。 新加坡癌症科学研究所